Alnylam Pharmaceuticals, Inc. v. Pfizer Inc.
1:22-cv-00924
Overview
Parties
Defendant
BioNTech Manufacturing GmbH NPE (Individual / Inventor)
Represented By
0 Attorneys ListedPharmacia & Upjohn Co. LLC Operating Company
Represented By
0 Attorneys ListedPlaintiff
Alnylam Pharmaceuticals, Inc. Operating Company
Represented By
5 Attorneys ListedMcDermott Will & Emery LLP
The Brandywine Building, 1000 N. West Street
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 7 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 11,382,979 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2011615681 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2012616232 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,061,063 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 10,369,226 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 11,071,784 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 11,246,933 B1 | US Continuation / Sibling | View Official Patent → |
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.
Alnylam Pharmaceuticals, Inc. v. Pfizer Inc.
Alnylam Pharmaceuticals, Inc. v. Moderna, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US11382979
Biodegradable lipids for the delivery of active agents
|
Filed: 2021-12-17
Issued: 2022-07-12
|
Active (15.1 yrs remaining)
Expires: 2041-12-17
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).